Skip to main content

Atugen Strikes Contract Research Deal with Eisai Subsidiary

NEW YORK, July 8 (GenomeWeb News) - Atugen said this week that it has signed a contract research agreement with Eisai London Research Laboratories, a subsidiary of Japanese drug maker Eisai.

 

Under the deal, Atugen will use its gene-silencing technologies to validate and optimize undisclosed drug targets provided by Eisai. Additional terms, including the financials, were not disclosed.

 

This is Atugen's second research agreement this year with a Japanese pharmaceutical company. The company also announced a multi-year agreement with Sankyo on May 17.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.